Download MendeleyDiscovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Caldwell, R., Liu-Bujalski, L., Qiu, H., Mochalkin, I., Jones, R., Neagu, C., Goutopoulos, A., Grenningloh, R., Johnson, T., Sherer, B., Gardberg, A., Follis, A.V., Morandi, F., Head, J.(2018) Bioorg Med Chem Lett 28: 3419-3424
- PubMed: 30290988
- DOI: https://doi.org/10.1016/j.bmcl.2018.09.033
- Primary Citation of Related Structures:
6DI0, 6DI1 - PubMed Abstract:
Btk is an attractive target for the treatment of a range of Bcell malignancies as well as several autoimmune diseases such as murine lupus and rheumatoid arthritis. Several covalent irreversible inhibitors of Btk are currently in development including ibrutinib which was approved for treatment of B-cell malignancies. Herein, we describe our efforts using X-ray guided structure based design (SBD) to identify a novel chemical series of covalent Btk inhibitors. The resulting pyridine carboxamides were potent and selective inhibitors of Btk having excellent enzymatic and cellular inhibitory activity.
Organizational Affiliation:
EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica 01821, MA, USA. Electronic address: richard.caldwell@emdserono.com.
